Assessment of GSK1904529A as a promising anti-osteosarcoma agent

• Published in: Oncotarget 2017-07, Vol.8 (30), p.49646-49654
• Main Authors: Fei, Hao-Dong, Yuan, Qi, Mao, Li, Chen, Feng-Li, Cui, Zhao-Hui, Tao, Sha, Ji, Feng
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - pharmacology; Apoptosis - drug effects; Caspase 3; Cell Cycle - drug effects; Cell Line, Tumor; Cell Proliferation - drug effects; Disease Models, Animal; Gene Knockdown Techniques; Humans; Imidazoles - pharmacology; Male; Mice; Osteosarcoma - drug therapy; Osteosarcoma - metabolism; Osteosarcoma - pathology; Pyridines - pharmacology; Receptor, IGF Type 1 - antagonists & inhibitors; Receptor, IGF Type 1 - genetics; Receptor, IGF Type 1 - metabolism; Research Paper; Signal Transduction - drug effects; Xenograft Model Antitumor Assays
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.17911

The insulin growth factor-I receptor (IGF1R) signaling is a key mechanism for osteosarcoma (OS) cell proliferation. GSK1904529A is a novel small molecule IGF1R kinase inhibitor. Its activity against OS cells was tested. In both established OS cell lines (Saos-2 and MG-63) and primary human OS cells, treatment with GSK1904529A (at nM concentrations) significantly inhibited cell proliferation. At the molecular level, GSK1904529A almost completely blocked IGF1R activation in OS cells, and inhibited downstream AKT-ERK activation. IGF1R silence by targeted shRNA also inhibited AKT-ERK activation and Saos-2 cell proliferation. Significantly, GSK1904529A was unable to further inhibit proliferation of IGF1R-silenced Saos-2 cells. In vivo, GSK1904529A administration orally inhibited Saos-2 tumor growth in nude mice. Together, these results suggest that targeting IGF1R by GSK1904529A inhibits OS cell growth in vitro and in vivo.